IMPORTANT MESSAGE: The 2014-2019 phase of the HHQI National Campaign concluded on July 17, 2019. Click here for details.
COVID-19: For the latest updates and information on the COVID-19 pandemic, please visit the Quality Insights website.
About Us > FAQs > HHCDR > Aspirin

HHCDR: Aspirin Measure FAQ

  1. What are the criteria for a patient to be selected for the Aspirin measure?

    The patient must have a diagnosis of Ischemic Vascular Disease (IVD) (view ICD-9 & ICD-10 codes) AND be older than 18 years.

  2. My patient is taking warfarin. Does this count as a ‘yes’?

    No. The only medications other than aspirin that will count as a ‘yes’ are clopidogrel, prasugrel, ticagrelor, or ticlopidine.

  3. Why doesn't warfarin, apixaban or rivaroxaban ‘count’ as a ‘yes’ in the HHCDR for clot prevention?

    The Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic measure is focused on appropriate first line treatment for patients with IVD and therefore includes aspirin or traditional antiplatelet therapies. Warfarin and the other medications do not meet the current criteria for Physician Quality Reporting System (PQRS) reporting on which the HHQI Measures are based. As the national PQRS criteria are updated, the HHQI Measures will be updated to align.


  4. If a patient has HITT (heparin induced thrombocytopenia), they probably shouldn’t be on aspirin.  Can I count this as ‘contraindicated’?

    Only if the chart documentation notes this is the reason per an MD order or conversation noted by the clinician.  The abstractor is not to make assumptions for any questions.